CLAIMS

We claim:

1. A compound of general formula (I):



(I)

optionally further substituted in the saturated ring by one or more alkyl substituents, in which:

R^1 represents hydrogen, R^4, $-C(=Y)-NHR^4$, $-SO_2NHR^4$, $-C(=Z^1)-R^4$, $-SO_2-R^4$ or $-C(=Z^1)-OR^4$;

R^2 represents hydrogen, cyano, halogen or $-C\equiv C-R^5$;

R^3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxycarbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or $-C(=O)-NY^1Y^2$;

R^4 represents alkyl, cycloalkyl, cycloalkenyl or heterocycloalkyl each optionally substituted by one or more groups selected from aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, $-C(=O)-OR^8$, $-C(=O)-R^9$, $-C(=O)-NY^3Y^4$, $-NY^1Y^2$, $-N(R^{10})-C(=O)-R^9$, $-N(R^{10})-C(=O)-OR^9$, $-N(R^{10})-SO_2-R^9$ or $-Z^2R^8$; or R^4 represents aryl or heteroaryl each optionally substituted by one or more groups selected from alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R^7, $-C(=O)-NY^3Y^4$, $-C(=O)-OR^8$, $-C(=O)-R^{11}$, $-NY^3Y^4$, $-N(R^{10})-C(=O)-R^9$, $-N(R^{10})-C(=O)-NY^5Y^6$, $-N(R^{10})-C(=O)-OR^9$, $-N(R^{10})-SO_2-R^9$, $-N(R^{10})-SO_2-NY^5Y^6$, $-SO_2-NY^3Y^4$ and $-Z^2R^{12}$;

R^5 represents hydrogen or alkyl;

R^6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl;

R^7 represents alkyl, cycloalkyl or cycloalkylalkyl each optionally substituted by one or more substituents selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CHO (or a 5-, 6- or 7-membered cyclic acetal derivative

thereof), -C(=O)-NY^1Y^2, -C(=O)-OR^8, -NY^3Y^4, -$N(R^{10})$-C(=O)-R^9, -$N(R^{10})$-C(=O)-NY^3Y^4, -$N(R^{10})$-SO_2-R^9, -$N(R^{10})$-SO_2-NY^3Y^4 and -OR^9;

R^8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl;

R^9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R^{10} represents hydrogen or lower alkyl;

R^{11} represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by -NY^1Y^2;

R^{12} represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by one or more substituents selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CHO (or a 5-, 6- or 7-membered cyclic acetal derivative thereof), -C(=O)-NY^1Y^2, -C(=O)-OR^8, -NY^1Y^2, -$N(R^{10})$-C(=O)-R^9, -$N(R^{10})$-C(=O)-NY^3Y^4, -$N(R^{10})$-SO_2-R^9, -$N(R^{10})$-SO_2-NY^3Y^4 and -OR^9;

Y represents O, S or NCN;

Y^1 and Y^2 are independently hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group -NY^1Y^2 may form 5-7 membered ring which optionally contains an additional heteroatom selected from O, S or NR^6;

Y^3 and Y^4 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -C(=O)-NY^5Y^6, -C(=O)-OR^8, -NY^5Y^6, -$N(R^6)$-C(=O)-R^9, -$N(R^6)$-C(=O)-NY^5Y^6, -$N(R^6)$-SO_2-R^9, -$N(R^6)$-SO_2-NY^5Y^6 and -OR^9; or the group -NY^3Y^4 may form a cyclic amine;

Y^5 and Y^6 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY^5Y^6 may form a cyclic amine;

Z represents O or S;

Z^1 represents O or S;

Z^2 represents O or $S(O)_p$;

n is zero or an integer 1 or 2;

m is 1 or 2;

p is 1 or 2;

and the corresponding N-oxides, and the prodrugs; and the pharmaceutically acceptable salts and solvates of compounds of formula (I) and their N-oxides and their prodrugs.

2. The compound according to claim 1, of formula (Ia):



(Ia)

in which R^2, R^3, R^4 and Y are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Ia) and their N-oxides and their prodrugs.

3. The compound according to claim 1, of formula (Ib):



(Ib)

in which R^2, R^3 and R^4 are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Ib) and their N-oxides and their prodrugs.

4. The compound according to claim 1, of formula (Ic):



(Ic)

in which R^2, R^3 and R^4 are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Ic) and their N-oxides and their prodrugs.

5. The compound according to claim 1, of formula (ICC):



(ICC)

in which R^2, R^3 and R^{4C} represent NHR4 with R^4 as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Ic) and their N-oxides and their prodrugs.

6. The compound according to claim 1, of formula (Id):-



(Id)

in which R^2, R^3 and R^4 are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Id) and their N-oxides and their prodrugs.

7. The compound according to claim 1, of formula (Ie):



(Ie)

in which R^2 and R^3 are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (Ie) and their N-oxides and their prodrugs.

8. The compound according to claim 1, of formula (If):



(If)

in which R^2, R^3 and R^4 are as hereinbefore defined; and the corresponding N-oxides, and the prodrugs; and pharmaceutically acceptable salts and solvates of compounds of formula (If) and their N-oxides and their prodrugs.

9. A pharmaceutical composition comprising, as active principle, at least one compound according to claim 1.

10. A method of treating a disease state capable of being modulated by the inhibition of JNK activity, comprising: administering to a patient in need thereof an effective dose of a compound according to claim 1.